Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 441

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 2
Chunk 441
---
 applications or grant licenses on terms that may not be favorable to us. We may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time.

Off-Balance Sheet Transactions

At December 31, 2024, the Company did not have any transactions, obligations or relationships that could be considered off-balance sheet arrangements.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

 51Table of Contents

Item 8. Financial Statements and Supplementary Data.

Index to Financial Statements

ENDRA Life Sciences Inc.

December 31, 2024

  Page     Report of Independent Registered Public Accounting Firm - (Firm ID 587) F-1     Consolidated Balance Sheets as of December 31, 2024 and 2023 F-2     Consolidated Statements of Operations for the years ended December 31, 2024 and 2023 F-3     Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2024 and 2023 F-4     Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023 F-5     Notes to Consolidated Financial Statements for the years ended December 31, 2024 and 2023 F-6 

 52Table of Contents

 RBSM LLP  Houston Office: 7915 FM 1960 West, Ste. 220Houston, Texas 77070 www.rbsmllp.com 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of

ENDRA Life Sciences Inc. and Subsidiaries

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of ENDRA Life Sciences Inc. and Subsidiaries (collectively, the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations, shareholders’ equity and cash flows for each of the two years in the period ended December 31, 2024, and the related notes and schedules (collectively referred to as the “financial statements”).  In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023